Regeneron Pharmaceuticals (REGN) Net Margin (2009 - 2026)

Regeneron Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 20.17% for Q1 2026.

• On a quarterly basis, Net Margin fell 653.0% year-over-year to 20.17% in Q1 2026; TTM through Mar 2026 was 29.65%, a 229.0% decrease from a year earlier, with the FY2025 full-year figure at 31.41%, up 34.0% from the prior year.
• Net Margin fell to 20.17% in Q1 2026 per REGN's latest filing, from 21.74% in the prior quarter.
• Across five years, Net Margin topped out at 1947.0% in Q1 2022 and bottomed at 20.17% in Q1 2026.
• The 5-year median for Net Margin is 30.66% (2023), against an average of 212.23%.
• Across the five-year window, Net Margin surged 190290 bps in 2022 and tumbled 192114 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 1197.1% in 2022, then slumped by 97 bps to 33.77% in 2023, then dropped by 28 bps to 24.22% in 2024, then decreased by 10 bps to 21.74% in 2025, then dropped by 7 bps to 20.17% in 2026.
• Per Business Quant, the three latest REGN Net Margin figures stand at 20.17% (Q1 2026), 21.74% (Q4 2025), and 38.89% (Q3 2025).